Taro Pharmaceutical Industries Ltd. (TARO)


NYSE - NYSE Real Time Price. Currency in USD
126.600.00 (0.00%)
At close: 4:02 PM EDT
People also watch:
SCRILCIIPXLUTHRTEVA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open126.91
Prev Close126.60
Bid126.51 x 300
Ask126.59 x 400
Day's Range124.57 - 127.59
52wk Range122.99 - 157.99
1y Target EstN/A
Market Cap5.41B
P/E Ratio (ttm)9.89
Beta0.38
Volume319,300
Avg Vol (3m)284,523
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube6 days ago

    ETF’s with exposure to Taro Pharmaceutical Industries Ltd. : August 25, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Taro Pharmaceutical Industries Ltd. Here are 5 ETF’s with the largest exposure to TARO-US. Comparing the performance and risk of Taro Pharmaceutical Industries Ltd. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • Business Wire12 days ago

    Taro Announces Completion of $250 Million Share Repurchase Program

    Taro Pharmaceutical Industries Ltd. announced today that it recently completed its $250 million share repurchase program. The company bought back 1,801,099 of its ordinary shares in open market transactions at an average price of $138.80 per share.

  • Taro Pharmaceutical Industries Ltd. :TARO-US: Earnings Analysis: Q1, 2017 By the Numbers : August 12, 2016
    Capital Cube19 days ago

    Taro Pharmaceutical Industries Ltd. :TARO-US: Earnings Analysis: Q1, 2017 By the Numbers : August 12, 2016

    Categories: Yahoo Finance Click here to see latest analysis Taro Pharmaceutical Industries Ltd. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Taro Pharmaceutical Industries Ltd. – Mylan N.V., Pfizer Inc., Merck & Co., Inc., Johnson & Johnson, Teva Pharmaceutical Industries Limited Sponsored ADR, GlaxoSmithKline plc Sponsored ... Read more (Read more...)